{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:22:37Z","timestamp":1790011357041,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.antiviral.2008.09.003","type":"journal-article","created":{"date-parts":[[2008,10,22]],"date-time":"2008-10-22T09:19:39Z","timestamp":1224667179000},"page":"1-5","source":"Crossref","is-referenced-by-count":17,"title":["Perspectives on antiviral drug development"],"prefix":"10.1016","volume":"81","author":[{"given":"Mark A.","family":"Wainberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2008.09.003_bib1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0065-3527(08)60306-1","article-title":"HIV-1 integrase: structural organization, conformational changes, and catalysis","volume":"52","author":"Asante-Appiah","year":"1999","journal-title":"Adv. Virus Res."},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2008.09.003_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350801302S04","article-title":"Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment","volume":"13","author":"Bennett","year":"2008","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.antiviral.2008.09.003_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/095632020801900101","article-title":"Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations","volume":"19","author":"Biswas","year":"2008","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.antiviral.2008.09.003_bib4","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1097\/01.aids.0000232228.88511.0b","article-title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture","volume":"20","author":"Brenner","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2008.09.003_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/430709","article-title":"Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection","volume":"41","author":"Campbell","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.09.003_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.antiviral.2008.09.003_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2893.2007.00887.x","article-title":"Old and emerging therapies in chronic hepatitis C: an update","volume":"15","author":"Deutsch","year":"2008","journal-title":"J. Viral Hepatitis"},{"key":"10.1016\/j.antiviral.2008.09.003_bib8","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1128\/AAC.47.11.3377-3383.2003","article-title":"Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase","volume":"11","author":"Diallo","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.09.003_bib9","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1128\/AAC.46.7.2254-2256.2002","article-title":"Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1","volume":"46","author":"Diallo","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.09.003_bib10","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2008.09.003_bib11","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/00126334-200412150-00009","article-title":"Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation","volume":"37","author":"Eron","year":"2004","journal-title":"J. Acquired Immunodeficiency Syndromes"},{"key":"10.1016\/j.antiviral.2008.09.003_bib12","first-page":"556","article-title":"The M184V mutation: what it does, how to prevent it, and what to do with it when it\u2019s there","volume":"16","author":"Gallant","year":"2006","journal-title":"The AIDS Reader"},{"key":"10.1016\/j.antiviral.2008.09.003_bib13","doi-asserted-by":"crossref","unstructured":"Greene, W.C., Debyser, Z., Ikeda, Y., Freed, O., Stephens, E., Yonemoto, W., Buckheit, R., Este, J.A., Cihlar, T., 2008. Novel targets for HIV therapy. Antiviral Res., in press.","DOI":"10.1016\/j.antiviral.2008.08.003"},{"key":"10.1016\/j.antiviral.2008.09.003_bib14","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/QAD.0b013e328302f3b5","article-title":"Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen","volume":"22","author":"Harris","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2008.09.003_bib15","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(05)66553-1","article-title":"Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials","volume":"365","author":"Hodson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2008.09.003_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/135965350801300102","article-title":"Health-related quality of life and tolerability in treatment-experienced HIV-1infected patients on tipranavir versus comparator regimens","volume":"13","author":"Huang","year":"2008","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.antiviral.2008.09.003_bib17","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/nar\/3.8.2143","article-title":"Metabolism of pyrimidine-l-nucleosides","volume":"3","author":"Jurovcik","year":"1976","journal-title":"Nucleic Acid Res."},{"key":"10.1016\/j.antiviral.2008.09.003_bib18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1358\/dot.2007.43.7.1086178","article-title":"The first once-daily single-tablet regimen for the treatment of HIV-infected patients","volume":"43","author":"Killingley","year":"2007","journal-title":"Drugs Today"},{"key":"10.1016\/j.antiviral.2008.09.003_bib19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/00002030-200303280-00007","article-title":"A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy","volume":"17","author":"Lalezari","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2008.09.003_bib20","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1053\/j.gastro.2007.04.062","article-title":"HCV findings presented at EASL: long-term follow-up and the criteria of a cure","volume":"132","author":"Lang","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2008.09.003_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/589289","article-title":"Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents","volume":"47","author":"MacArthur","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.antiviral.2008.09.003_bib22","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1128\/AAC.00133-08","article-title":"Tipranavir\/ritonavir genotypic resistance score in protease inhibitor-experienced patients","volume":"52","author":"Marcelin","year":"2008","journal-title":"Antimicrob. Agents Chemother"},{"issue":"9","key":"10.1016\/j.antiviral.2008.09.003_bib23","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1128\/AAC.00498-08","article-title":"Combinations of a cyclophilin inhibitor NIM811 with HCV NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance","volume":"52","author":"Mathy","year":"2008","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.antiviral.2008.09.003_bib24","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.clinthera.2007.08.016","article-title":"Darunavir: a nonpeptidic antiretroviral protease inhibitor","volume":"29","author":"McCoy","year":"2007","journal-title":"Clin. Therap."},{"key":"10.1016\/j.antiviral.2008.09.003_bib25","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1371\/journal.pmed.0040305","article-title":"Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment","volume":"4","author":"Nunn","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2008.09.003_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1086\/518939","article-title":"John F. Enders lecture 2006: antivirals for influenza","volume":"196","author":"Ong","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.09.003_bib27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/135965350801300214","article-title":"Virological response to darunavir\/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study)","volume":"13","author":"Pellegrin","year":"2008","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.antiviral.2008.09.003_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/156802608783955647","article-title":"New developments in the discovery of agents to treat hepatitis C","volume":"8","author":"Ronn","year":"2008","journal-title":"Curr. Topics Med. Chem."},{"issue":"Suppl. 3","key":"10.1016\/j.antiviral.2008.09.003_bib29","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1086\/533414","article-title":"Management of hepatic complications in HIV-infected persons","volume":"197","author":"Sulkowski","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.09.003_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.antiviral.2007.11.010","article-title":"Characterization of resistance mutations against HCV ketoamide protease inhibitors","volume":"77","author":"Tong","year":"2008","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.antiviral.2008.09.003_bib31","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1371\/journal.pone.0000152","article-title":"The emergence of HIV transmitted resistance in Botswana: \u201cwhen will the WHO detection threshold be exceeded?\u201d","volume":"2","author":"Vardavas","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2008.09.003_bib32","doi-asserted-by":"crossref","first-page":"9835","DOI":"10.1073\/pnas.0711813105","article-title":"The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics","volume":"105","author":"Wilson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2008.09.003_bib33","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1128\/AAC.01208-07","article-title":"Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors","volume":"52","author":"Wyles","year":"2008","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354208003951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354208003951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T23:35:55Z","timestamp":1709336155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354208003951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0166354208003951"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2008.09.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}